SCHEMBL25129492

SCHEMBL25129492

CC(C)C(=O)CN(C)CCN(C)CCN(C)CCN(C)C(=O)CN(C)CCN(C)CCN(C)CCN(C)C(=O)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25129614 0.93 DPP4 (0.32) —
SCHEMBL25129540 0.93 DPP4 (0.32) —
SCHEMBL25129494 0.88 CA12 (0.38) —
SCHEMBL25132339 0.83 — —
SCHEMBL25129701 0.83 — —
SCHEMBL25129700 0.79 KMT2A (0.35) —
SCHEMBL16384473 0.76 CA12 (0.48) —
SCHEMBL25132435 0.76 CA12 (0.48) —
SCHEMBL7942433 0.75 KDM4E (0.36) —
SCHEMBL25132934 0.74 KDM5A (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023057814-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS VINCERX PHARMA GMBH (DE) 2023-04-13 — — WO disclosed
WO-2023057813-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS VINCERX PHARMA GMBH (DE) 2023-04-13 — — WO disclosed
WO-2023057812-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER VINCERX PHARMA GMBH (DE) 2023-04-13 — — WO disclosed
Send feedback